Revealing the potential of intranasally administered orexin A (Hypocretin-1)

Molecular Interventions

Volumn 8, Issue 3, 2008, Pages 133-137

  Hallschmid, Manfred ^a   Born, Jan ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A;

AKATHISIA; ALERTNESS; CATAPLEXY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM FUNCTION; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DOG; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; EMOTION; FEEDBACK SYSTEM; FEEDING BEHAVIOR; FOOD INTAKE; GENETIC CODE; HOMEOSTASIS AND REGULATION; HUMAN; HYPOPHAGIA; IRON METABOLISM; NARCOLEPSY; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; RHESUS MONKEY; RODENT; SHORT TERM MEMORY; SLEEP DEPRIVATION; SLEEP WAKING CYCLE; SPECIES COMPARISON; SQUIRREL MONKEY; STATISTICAL SIGNIFICANCE; WAKEFULNESS;

ADMINISTRATION, INTRANASAL; ANIMALS; DRUG ADMINISTRATION ROUTES; HAPLORHINI; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMORY; MICE; NEURONS; NEUROPEPTIDES; SLEEP DEPRIVATION;

EID: 49649118996     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.8.3.5     Document Type: Review

References (39)

1. Sakurai, T. The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171-181 (2007). A very comprehensive and lucid review by one of the authors who, in 1998, first described the orexin system and its implication in the regulation of food intake.
2. Sweet, D.C., Levine, A.S., Billington, C.J., and Kotz, C.M. Feeding response to central orexins. Brain Res. 821, 535-538 (1999).
3. Haynes, A.C., Jackson, B., Overend, P., Buckingham, R.E., Wilson, S., Tadayyon, M., and Arch, J.R. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 20, 1099-1105 (1999).
4. Adamantidis, A.R., Zhang, F., Aravanis, A.M., Deisseroth, K., and de, L.L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450, 420-424 (2007). A recent in-vivo study showing that optogenetic photostimulation of orexin neurons in mice increases the probability of transition to wakefulness from sleep, establishing a causal relationship between orexinergic activity and awakening.
5. Mileykovskiy, B.Y., Kiyashchenko, L.I., and Siegel, J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46, 787-798 (2005). This study in rats elegantly shows that orexin cells are silent in slow wave sleep and tonic REM sleep while discharging during active wakefulness.
6. Yoshida, Y., Fujiki, N., Nakajima, T., Ripley, B., Matsumura, H., Yoneda, H., Mignot, E., and Nishino, S. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 14, 1075-1081 (2001).
7. Zeitzer, J.M., Buckmaster, C.L., Parker, K.J., Hauck, C.M., Lyons, D.M., and Mignot, E. Circadian and homeostatic regulation of hypocretin in a primate model: Implications for the consolidation of wakefulness. J. Neurosci. 23, 3555-3560 (2003).
8. Hagan, J.J., Leslie, R.A., Patel, S. et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U. S. A 96, 10911-10916 (1999). One of the first systematic studies indicating a tight interaction between orexinergic signaling to the locus coeruleus and the regulation of sleep/wake rhythmicity.
9. Moore, R.Y., Abrahamson, E.A., and Van Den, P.A. The hypocretin neuron system: An arousal system in the human brain. Arch. Ital. Biol. 139, 195-205 (2001).
10. Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., and Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39-40 (2000). This study together with other clinical observations provides evidence that human narcolepsy very likely results from the neurodegenerative malfunction of orexin neurons.
11. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P.J., Nishino, S., and Mignot, E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376 (1999).
12. Chemelli, R.M., Willie, J.T., Sinton, C.M. et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98, 437-451 (1999). References 11 and 12 show that a deficient orexin system results in a narcoleptic phenotype in dogs and mice.
13. Allen, R.P., Mignot, E., Ripley, B., Nishino, S., and Earley, C.J. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 59, 639-641 (2002).
14. Hening, W.A. Current guidelines and standards of practice for restless legs syndrome. Am. J. Med. 120, S22-S27 (2007).
15. Baier, P.C. and Trenkwalder, C. Circadian variation in restless legs syndrome. Sleep Med. 8, 645-650 (2007).
16. Winkelman, J.W. Considering the causes of RLS. Eur. J. Neurol. 13 Suppl 3, 8-14 (2006).
17. Brisbare-Roch, C., Dingemanse, J., Koberstein, R. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155 (2007). This paper demonstrates that blocking orexin receptors promotes sleep in rats, dogs and also in humans.
18. Takahashi, N., Okumura, T., Yamada, H., and Kohgo, Y. Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats. Biochem. Biophys. Res. Commun. 254, 623-627 (1999).
19. Kastin, A.J. and Akerstrom, V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. 289, 219-223 (1999).
20. John, J., Wu, M.F., and Siegel, J.M. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res. Online. 3, 23-28 (2000).
21. Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., and Nishino, S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26, 953-959 (2003). References 20 and 21 have yielded mixed results regarding the efficacy of systemically administered orexin A to reverse narcoleptic symptoms in dogs.
22. Deadwyler, S.A., Porrino, L., Siegel, J.M., and Hampson, R.E. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J. Neurosci. 27, 14239-14247 (2007).
23. Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., and Fehm, H.L. Sniffing neuropeptides: A transnasal approach to the human brain. Nat. Neurosci. 5, 514-516 (2002). This study shows that intranasally administered neuropeptides reach the CSF within 30 minutes after application but do not enter the circulation, which enables the direct examination of central nervous functions of neuropeptides in the absence of peripheral effects.
24. Hanson, L.R., Martinez, P.M., Taheri, S., Kamsheh, L., Mignot, E., and Frey II, W.H. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier and targets the brain: A new strategy for the treatment of narcolepsy. Drug Delivery Technology 4, 66-71 (2004).
25. Kiyashchenko, L.I., Mileykovskiy, B.Y., Maidment, N., Lam, H.A., Wu, M.F., John, J., Peever, J., and Siegel, J.M. Release of hypocretin (orexin) during waking and sleep states. J. Neurosci. 22, 5282-5286 (2002).
26. Ramsey, J.J., Kemnitz, J.W., Newton, W., Hagopian, K., Patterson, T.A., and Swick, A.G. Food intake in rhesus monkeys following central administration of orexins. Regul. Pept. 124, 209-214 (2005).
27. Salomon, R.M., Ripley, B., Kennedy, J.S., Johnson, B., Schmidt, D., Zeitzer, J.M., Nishino, S., and Mignot, E. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96-104 (2003).
28. Thorne, R.G., Pronk, G.J., Padmanabhan, V., and Frey, W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004).
29. Illum, L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11, 1-18 (2000). This in-depth account of the intranasal pathway for the delivery of therapeutic agents to the brain is an excellent introduction to the research field.
30. Thorne, R.G., Emory, C.R., Ala, T.A., and Frey, W.H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 692, 278-282 (1995).
31. Hallschmid, M., Benedict, C., Schultes, B., Fehm, H.L., Born, J., and Kern, W. Intranasal insulin reduces body fat in men but not in women. Diabetes 53, 3024-3029 (2004).
32. Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H.L., Born, J., and Kern, W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334 (2004).
33. Reger, M.A., Watson, G.S., Frey, W.H. et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol. Aging 27, 451-458 (2006).
34. Craft, S. Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 26 Suppl 1, 65-69 (2005).
35. Siegel, J.M. and Boehmer, L.N. Narcolepsy and the hypocretin system - where motion meets emotion. Nat. Clin. Pract. Neurol. 2, 548-556 (2006). A concise review of the orexin system with a particular focus on pathogenesis of and current treatment options for narcolepsy.
36. Obici, S., Zhang, B.B., Karkanias, G., and Rossetti, L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 8, 1376-1382 (2002).
37. Schwartz, M.W., and Porte, D., Jr. Diabetes, obesity, and the brain. Science 307, 375-379 (2005).
38. Hallschmid, M., Benedict, C., Schultes, B., Perras, B., Fehm, H.L., Kern, W., and Born, J. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul. Pept., in press (2008).
39. Porrino, L.J., Daunais, J.B., Rogers, G.A., Hampson, R.E., and Deadwyler, S.A. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS. Biol. 3, e299 (2005).